PARP Inhibitors in Ovarian Cancer: Experts Discuss Patient Cases and the Current Paradigm

In this episode, Nicoletta Colombo, MD; Philipp Harter, MD, PhD; and  Alexandra Leary, MD, PhD, discuss patient cases from a live webinar on the current paradigm and long-term benefits of PARPi therapy in the treatment of ovarian cancer. Topics include:Maintenance therapy in ovarian cancerSOLO1, PRIMA, PAOLO-1 clinical dataRole of bevacizumab in treatment of ovarian cancerPresenters:Nicoletta Colombo, MDProfessor of Obstetrics and GynecologyUniversity of Milan-BicoccaEuropean Institute of OncologyMilan, ItalyPhilipp Harter, MD, PhDDeputy DirectorDepartment of Gynecology and Gynecologic OncologyEvang. Kliniken Essen-MitteEssen, GermanyAlexandra Leary, MD, PhDMedical Oncologist and Team LeaderGynecology Translational Research LabDepartment of MedicineGustave Roussy Cancer CenterParis, FranceContent based on an online CME program supported by an educational grant from AstraZeneca.New Perspectives in Ovarian Cancer: Current Paradigm and Long-term Benefits of PARPi Therapyhttps://bit.ly/3aF8Lui 

There are no comments yet.

Please log in to write the first comment.